Denali Capital Acquisition CORP 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
Semnur Pharmaceuticals, a late-stage biopharmaceutical company, reported significant losses and a going concern doubt, while advancing its lead non-opioid pain candidate, SP-102, into a second Phase 3 trial.
Denali Capital Acquisition Corp.'s annual report reveals substantial doubt about its ability to continue as a going concern, despite efforts to merge with Semnur Pharmaceuticals.
Denali Capital Acquisition Corp.'s annual report outlines the company's financial status, progress on its merger with Longevity Biomedical, and ongoing efforts to meet Nasdaq listing requirements.